Vertex Pharmaceuticals (VRTX) Other Non-Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals has reported Other Non-Current Liabilities for 18 years, with the latest figure at $1.3 billion in Q2 2026.

• On a quarterly basis, Other Non-Current Liabilities rose 5.39% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 5.39% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 25.12% from the prior year.
• Other Non-Current Liabilities was $1.3 billion for Q2 2026 at Vertex Pharmaceuticals, roughly flat from $1.3 billion in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $1.3 billion in Q4 2025, with the low at $127.2 million in Q3 2022.
• Average Other Non-Current Liabilities over 5 years is $844.4 million, with a median of $877.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities slumped 32.52% in 2022, then surged 583.41% in 2023.
• Over 5 years, Other Non-Current Liabilities stood at $685.8 million in 2022, then increased by 27.98% to $877.7 million in 2023, then increased by 15.6% to $1.0 billion in 2024, then grew by 25.12% to $1.3 billion in 2025, then fell by 0.76% to $1.3 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.3 billion (Q2 2026), $1.3 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.